CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers.
Teh SSK, Bowland K, Bennett A, Halper-Stromberg E, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Scharpf RB, Roberts NJ, Eshleman JR
bioRxiv. 2023 Oct 10:2023.04.15.537042. doi: 10.1101/2023.04.15.537042. Preprint. PubMed Article
Teh SSK, Bowland K, Bennett A, Halper-Stromberg E, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Scharpf RB, Roberts NJ, Eshleman JR
bioRxiv. 2023 Oct 10:2023.04.15.537042. doi: 10.1101/2023.04.15.537042. Preprint. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 211471 | pLenti_Cas9_T2A_mNeonGreen_P2A_blasticidin | lentiviral tricistronic complex expressing Cas9, mNeonGreen, and blasticidin resistance |